Blocking the PD‐L1/PD‐1 checkpoint enhanced the killing effect of radiotherapy on nasopharyngeal carcinoma cells, even though this killing effect was achieved by enhancing the activity of NK cells.[28] Theoretically, TPP‐LND@Lip is possible to play a similar role in other cancers treated by radiotherapy with high PD‐L1 expression. The gene discussed is CD274; the disease is cancer.